Bristol Myers Squibb, SystImmune’s Iza-Bren Hits Primary Endpoint In Phase 3 PANKU-Lung01 Interim Analysis, Median PFS 11.1 Versus 5.7 Months (HR 0.40) Over Platinum Chemotherapy In EGFR-Mutated NSCLC
Benzinga Newsdesk 1 week ago
News
Late-breaking results to be presented in an oral presentation at ESMO 2026PANKU-Lung01 is the first Phase 3 trial to evaluate a dual-targeting EGFRxHER3 bispecific antibody-drug conjugate in this patient
Late-breaking results to be presented in an oral presentation at ESMO 2026
PANKU-Lung01 is the first Phase 3 trial to evaluate a dual-targeting EGFRxHER3 bispecific antibody-drug conjugate in this patient population
Iza-bren, a potentially first-in-class dual-targeting EGFRxHER3 bispecific antibody-drug conjugate, has now demonstrated clinical benefit in five distinct tumor types